Drug
QL0911
QL0911 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 32 (40.0%)
Trials by Status
not_yet_recruiting120%
completed360%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruitingphase_3
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT07455006
recruitingphase_2
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
NCT06456528
completedphase_2
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
NCT05554913
completedphase_2
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
NCT05851027
completedphase_3
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
NCT05621330
Clinical Trials (5)
Showing 5 of 5 trials
NCT07455006Phase 3
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT06456528Phase 2
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
NCT05554913Phase 2
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
NCT05851027Phase 2
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
NCT05621330Phase 3
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5